ATXI · CIK 0001644963
AVENUE THERAPEUTICS, INC.
Annual figures as reported, FY2015–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
$1.4M
Net income
−$2.9M
▲ +75.0% vs FY2024
Operating cash flow
−$1.8M
▲ +79.7% vs FY2024
Diluted EPS
−$0.93
▲ +94.1% vs FY2024
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Sep ’25 quarter
$0
Net income — Mar ’26 quarter
−$695K
▲ +62.5% vs Mar ’25
Diluted EPS — trailing 12 months
−$1.01
▼ −108.0% vs Mar ’24
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Sep ’25 | $0 | — | — | −$683K | — | −$0.21 |
| Jun ’25 | $1.4M | — | — | $335K | 23.9% | — |
| Sep ’24 | $0 | — | — | −$3.1M | — | −$1.92 |
| Jun ’24 | $0 | — | — | −$2.7M | — | −$6.43 |
Profitability & returns
quality of earningsReturns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Shareholder returns
capital allocationCapital returned
Cash paid out as dividends and share repurchases
Buybacks
Diluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedShare count change (split-adjusted)
+184.5%
5y
Key ratios
derived per fiscal year| Fiscal year | Op. margin | Net margin | ROE | ROA |
|---|---|---|---|---|
| FY2025 | −219.6% | −207.2% | −158.8% | −99.2% |
| FY2024 | — | — | −416.6% | −436.1% |
| FY2023 | — | — | −663.0% | −566.9% |
| FY2022 | — | — | −91.0% | −51.9% |
| FY2021 | — | — | −108.1% | −94.2% |
| FY2020 | — | — | −218.4% | −158.7% |
| FY2019 | — | — | −381.0% | −290.6% |
| FY2018 | — | — | — | −476.2% |
| FY2017 | — | — | −63.3% | −55.3% |
| FY2016 | — | — | — | −1612.7% |
| FY2015 | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | $1.4M | — | −$3.1M | −$2.9M | −$0.93 | −$1.8M | — | $2.9M | $1.1M | $1.8M | $2.9M | — |
| FY2024 | $0 | — | −$11.3M | −$11.7M | −$15.79 | −$9.0M | — | $2.7M | $816K | $2.8M | $2.6M | — |
| FY2023 | — | — | −$14.5M | −$10.5M | −$73.48 | −$9.5M | — | $1.9M | $1.2M | $1.6M | $1.8M | — |
| FY2022 | — | — | −$8.0M | −$3.6M | −$1.63 | −$7.6M | — | $6.8M | $3.6M | $3.9M | $6.7M | — |
| FY2021 | — | — | −$3.7M | −$3.7M | −$3.30 | −$3.8M | — | $4.0M | $509K | $3.5M | $3.8M | — |
| FY2020 | — | — | −$5.2M | −$5.2M | −$4.65 | −$4.6M | — | $3.2M | $886K | $2.4M | $3.1M | — |
| FY2019 | — | — | −$26.3M | −$25.9M | −$24.75 | −$26.3M | — | $8.9M | $2.1M | $6.8M | $8.7M | — |
| FY2018 | — | — | −$21.8M | −$21.5M | −$31.50 | −$18.2M | — | $4.5M | $5.2M | −$631K | $2.7M | — |
| FY2017 | — | — | −$11.4M | −$12.3M | −$27.75 | −$6.8M | — | $22.2M | $2.8M | $19.4M | $11.8M | — |
| FY2016 | — | — | −$2.4M | −$3.2M | −$16.65 | −$1.6M | — | $197K | $8.4M | −$8.2M | $197K | — |
| FY2015 | — | — | — | — | — | — | — | — | — | $0 | $0 | — |
Latest filings
the most recent regulatory filings10-QQuarterly report2026-05-08 ↗10-KAnnual report2026-03-30 ↗8-KCurrent report — material event2026-02-23 ↗SCHEDULE 13G/ASEC filing2026-02-17 ↗4Insider ownership filing2026-01-06 ↗SCHEDULE 13D/ASEC filing2026-01-06 ↗8-KCurrent report — material event2025-12-31 ↗EFFECTSEC filing2025-12-16 ↗POS AMSEC filing2025-12-15 ↗RWSEC filing2025-12-15 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.